Cargando…

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

BACKGROUND: At present, it is not known whether targeting plus immunotherapy combined with transarterial chemoembolization (TACE) can improve the efficacy of hepatocellular carcinoma (HCC). The aim of this retrospective experiment was to explore the difference in clinical efficacy between antiangiog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Han, Su, Ke, Guo, Lu, Jiang, Yi, Xu, Ke, Gu, Tao, Chen, Jiali, Wu, Zhenying, Wang, Pan, Zhang, Xi, Yan, Yushan, Li, Siyuan, Wu, Xue, Han, Lei, He, Kun, Wen, Lianbin, Li, Bo, Han, Yunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395511/ https://www.ncbi.nlm.nih.gov/pubmed/37538403 http://dx.doi.org/10.2147/JHC.S415843

Ejemplares similares

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
por: Su, Ke, et al.
Publicado: (2022)

A propensity score matching study on survival benefits of radiotherapy in patients with inoperable hepatocellular carcinoma
por: Zeng, Hao, et al.
Publicado: (2023)

Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for ≤5cm hepatocellular carcinoma: Propensity score matching analysis
por: Jun, Baek Gyu, et al.
Publicado: (2018)

Sorafenib Combined with Transarterial Chemoembolization versus Transarterial Chemoembolization Alone for Advanced-Stage Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Hu, Hao, et al.
Publicado: (2014)

Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study
por: Su, Ke, et al.
Publicado: (2022)

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study
por: Peng, Tzu-Rong, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study
por: Ouyang, Tao, et al.
Publicado: (2021)

Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: A propensity score matching analysis
por: Guo, Zhe, et al.
Publicado: (2017)

Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period
por: Su, Ke, et al.
Publicado: (2023)

Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis
por: Bogdanovic, A., et al.
Publicado: (2021)

Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Chung, Sung Won, et al.
Publicado: (2021)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
por: Zhu, Di, et al.
Publicado: (2022)

Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study [Retraction]
Publicado: (2022)

Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study
por: Marinelli, Brett, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
por: Zhao, Chenghao, et al.
Publicado: (2023)

Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula
por: Cai, Liang, et al.
Publicado: (2022)

Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome and Risk Signature Analysis
por: Liu, Yiming, et al.
Publicado: (2021)

PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma
por: Su, Ke, et al.
Publicado: (2022)

Transarterial Chemoembolization (TACE) Combined with Sorafenib versus TACE Alone for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Study
por: Ren, Baosheng, et al.
Publicado: (2019)

Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study
por: Zhong, Chong, et al.
Publicado: (2018)

Comparison of Microwave Ablation and Transarterial Chemoembolization for Single-Nodule Hepatocellular Carcinoma Smaller Than 5cm: A Propensity Score Matching Analysis
por: Cui, Rui, et al.
Publicado: (2019)

Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
por: Jeong, Yuri, et al.
Publicado: (2015)

Tyrosine-kinase inhibitor combined with iodine-125 seed brachytherapy for hepatocellular carcinoma refractory to transarterial chemoembolization: a propensity-matched study
por: Guo, Yongjian, et al.
Publicado: (2023)

Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study
por: Guo, Peng, et al.
Publicado: (2022)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Transarterial chemoembolization vs. liver resection as initial treatment for hepatocellular carcinoma occurring exclusively in caudate lobe: A retrospective propensity matching analysis
por: YANG, BIAO, et al.
Publicado: (2022)

Prognostic role of ABO blood group in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization
por: Li, Qing, et al.
Publicado: (2018)

Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization
por: Yue, Xiaofei, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of Transarterial Chemoembolization with or without Lenvatinib for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score–Matched Analysis
por: Chen, Yu-Xing, et al.
Publicado: (2022)

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
por: Zhong, Bin-Yan, et al.
Publicado: (2023)

Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma
por: Guo, Jingjing, et al.
Publicado: (2021)

Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization
por: Yue, Xiaofei, et al.
Publicado: (2022)

Comparison of Treatment Response, Survival Profiles, as Well as Safety Profiles Between CalliSpheres(®) Microsphere Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Huge Hepatocellular Carcinoma
por: Duan, Xuhua, et al.
Publicado: (2022)

Not All Hepatocellular Carcinoma Patients with Microvascular Invasion After R0 Resection Could Be Benefited from Prophylactic Transarterial Chemoembolization: A Propensity Score Matching Study
por: Wang, Lei, et al.
Publicado: (2020)

Adjuvant transarterial chemoembolization timing after radical resection is an independent prognostic factor for patients with hepatocellular carcinoma
por: Sun, Hongfa, et al.
Publicado: (2023)

Transhepatectomy combined with arterial chemoembolization and transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a clinical prognostic analysis
por: Liu, Xin, et al.
Publicado: (2023)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Comparison of overall survival in patients with unresectable hepatic metastases with or without transarterial chemoembolization: A Propensity Score Matching Study
por: Wang, F. Y., et al.
Publicado: (2016)

A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study
por: Shiba, Shintaro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kc3521fntr72huanohc6una5bu